This segment focuses on the collection, processing, and long-term storage of umbilical cord blood stem cells. Global Cord Blood Corporation provides comprehensive services, including cord blood testing, processing, and storage under the direction of subscribers. The company operates cord blood banks in multiple provinces in China, ensuring adherence to stringent quality control measures and regulatory compliance. Research and development activities include improving processing techniques and exploring new applications for stored stem cells. The company's market position is strengthened by its extensive geographical coverage and partnerships within the healthcare sector. Future opportunities lie in expanding the range of services and exploring new applications of cord blood in regenerative medicine and cell therapy. The company is also focused on expanding its market share in China and the Asia-Pacific region.

This segment represents Global Cord Blood Corporation's strategic move into the cell therapy market. Through the acquisition of Cellenkos, Inc., the company is developing cellular medicines. This involves research and development of innovative cell-based therapies, including those for severe diseases. The company is focused on developing cellular medicines to suppress severe diseases. This segment leverages advanced technologies in cell processing, cryopreservation, and cell culture. The therapeutic areas of focus include hematological disorders and potentially other areas where cell therapy can provide significant patient benefits. The company is working on clinical trials and regulatory approvals for its cell therapy products. The company's competitive advantage lies in its established infrastructure and expertise in stem cell processing and storage, which can be leveraged for cell therapy development. Future opportunities include expanding the cell therapy pipeline and establishing strategic partnerships to accelerate product development and commercialization.